Interplay between EGFR, E-cadherin, and PTP1B in epidermal homeostasis

References

• Kulukian A, Fuchs E. Spindle orientation and epidermal morphogenesis. Philos Trans R Soc Lond B Biol Sci. 2013;368(1629):211. doi:10.1098/rstb.2013.0016.
   Web of Science ®Google Scholar
• Fuchs E. Epithelial skin biology: three decades of developmental biology, a hundred questions answered and a thousand new ones to address. Curr Top Dev Biol. 2016;116:357–221.
   PubMed Web of Science ®Google Scholar
• Tinkle CL, Lechler T, Pasolli HA, Fuchs E. Conditional targeting of E-cadherin in skin: insights into hyperproliferative and degenerative responses. Proc Natl Acad Sci U S A. 2004;101(2):552–557. doi:10.1073/pnas.0307437100.
   PubMed Web of Science ®Google Scholar
• Tunggal JA, Helfrich I, Schmitz A, Schwarz H, Günzel D, Fromm M, Kemler R, Krieg T, Niessen CM. E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions. EMBO J. 2005;24(6):1146–1156. doi:10.1038/sj.emboj.7600605.
   PubMed Web of Science ®Google Scholar
• Young P, Boussadia O, Halfter H, Grose R, Berger P, Leone DP, Robenek H, Charnay P, Kemler R, Suter U. E-cadherin controls adherens junctions in the epidermis and the renewal of hair follicles. EMBO J. 2003;22(21):5723–5733. doi:10.1093/emboj/cdg560.
   PubMed Web of Science ®Google Scholar
• Andl CD, Rustgi AK. No one-way street: cross-talk between e-cadherin and receptor tyrosine kinase (RTK) signaling: a mechanism to regulate RTK activity. Cancer Biol Ther. 2005;4(1):28–31. doi:10.4161/cbt.4.1.1431.
   PubMed Web of Science ®Google Scholar
• Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2):21–26. doi:10.1016/j.ijrobp.2003.11.041.
   PubMed Web of Science ®Google Scholar
• Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol. 1997;109(6):751–756. doi:10.1111/1523-1747.ep12340759.
   PubMed Web of Science ®Google Scholar
• Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. doi:10.1016/j.phrs.2013.11.002.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019;139:395–411. doi:10.1016/j.phrs.2018.11.014.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J, Ferguson KM. The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harb Perspect Biol. 2014;6(4):a020768. doi:10.1101/cshperspect.a020768.
   PubMed Web of Science ®Google Scholar
• Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014;24:26–34.
   PubMed Web of Science ®Google Scholar
• Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol. 2015;2(4):e1004969. doi:10.1080/23723556.2015.1004969.
   PubMed Web of Science ®Google Scholar
• Di Domenico M, Giordano A. Signal transduction growth factors: the effective governance of transcription and cellular adhesion in cancer invasion. Oncotarget. 2017;8(22):36869–36884. doi:10.18632/oncotarget.16300.
   PubMedGoogle Scholar
• Baumdick M, Brüggemann Y, Schmick M, Xouri G, Sabet O, Davis L, Chin JW, Bastiaens PIH. EGF-dependent re-routing of vesicular recycling switches spontaneous phosphorylation suppression to EGFR signaling. Elife. 2015;4:e12223. doi:10.7554/eLife.12223.
   PubMed Web of Science ®Google Scholar
• Mertins P, Eberl HC, Renkawitz J, Olsen JV, Tremblay ML, Mann M, Ullrich A, Daub H. Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics. 2008;7(9):1763–1777. doi:10.1074/mcp.M800196-MCP200.
   PubMed Web of Science ®Google Scholar
• Feldhammer M, Uetani N, Miranda-Saavedra D, Tremblay ML. PTP1B: a simple enzyme for a complex world. Crit Rev Biochem Mol Biol. 2013;48(5):430–445. doi:10.3109/10409238.2013.819830.
   PubMed Web of Science ®Google Scholar
• Wong LH, Eden ER, Futter CE. Roles for ER:endosome membrane contact sites in ligand-stimulated intraluminal vesicle formation. Biochem Soc Trans. 2018;46(5):1055–1062. doi:10.1042/BST20170432.
   PubMedGoogle Scholar
• Tonks NK, Diltz CD, Fischer EH. Characterization of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem. 1988;263(14):6731–6737. doi:10.1016/S0021-9258(18)68703-4.
   PubMed Web of Science ®Google Scholar
• Tonks NK, Diltz CD, Fischer EH. Purification of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem. 1988;263(14):6722–6730. doi:10.1016/S0021-9258(18)68702-2.
   PubMed Web of Science ®Google Scholar
• Shi K, Egawa K, Maegawa H, Nakamura T, Ugi S, Nishio Y, Kashiwagi A. Protein-tyrosine phosphatase 1B associates with insulin receptor and negatively regulates insulin signaling without receptor internalization. J Biochem. 2004;136(1):89–96. doi:10.1093/jb/mvh094.
   PubMed Web of Science ®Google Scholar
• Galic S, Hauser C, Kahn BB, Haj FG, Neel BG, Tonks NK, Tiganis T. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol. 2005;25(2):819–829. doi:10.1128/MCB.25.2.819-829.2005.
   PubMed Web of Science ®Google Scholar
• Haj FG, Markova B, Klaman LD, Bohmer FD, Neel BG. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J Biol Chem. 2003;278(2):739–744. doi:10.1074/jbc.M210194200.
   PubMed Web of Science ®Google Scholar
• Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3–20. doi:10.1002/1878-0261.12155.
   PubMed Web of Science ®Google Scholar
• Bentires-Alj M, Neel BG. Protein-tyrosine phosphatase 1B is required for HER2/ Neu –Induced breast cancer. Cancer Res. 2007;67(6):2420–2424. doi:10.1158/0008-5472.CAN-06-4610.
   PubMed Web of Science ®Google Scholar
• Lessard L, Stuible M, Tremblay ML. The two faces of PTP1B in cancer. Biochim Biophys Acta. 2010;1804(3):613–619. doi:10.1016/j.bbapap.2009.09.018.
   PubMed Web of Science ®Google Scholar
• Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol. 2005;6(8):622–634. doi:10.1038/nrm1699.
   PubMed Web of Science ®Google Scholar
• Lecuit T, Yap AS. E-cadherin junctions as active mechanical integrators in tissue dynamics. Nat Cell Biol. 2015;17(5):533–539. doi:10.1038/ncb3136.
   PubMed Web of Science ®Google Scholar
• Niessen CM, Leckband D, Yap AS. Tissue organization by cadherin adhesion molecules: dynamic molecular and cellular mechanisms of morphogenetic regulation. Physiol Rev. 2011;91(2):691–731. doi:10.1152/physrev.00004.2010.
   PubMed Web of Science ®Google Scholar
• Coopman P, Djiane A. Adherens junction and E-Cadherin complex regulation by epithelial polarity. Cell Mol Life Sci. 2016;73(18):3535–3553. doi:10.1007/s00018-016-2260-8.
   PubMed Web of Science ®Google Scholar
• Watabe M, Nagafuchi A, Tsukita S, Takeichi M. Induction of polarized cell-cell association and retardation of growth by activation of the E-cadherin-catenin adhesion system in a dispersed carcinoma line. J Cell Biol. 1994;127(1):247–256. doi:10.1083/jcb.127.1.247.
   PubMed Web of Science ®Google Scholar
• Padmanaban V, Krol I, Suhail Y, Szczerba BM, Aceto N, Bader JS, Ewald AJ. E-cadherin is required for metastasis in multiple models of breast cancer. Nature. 2019;573(7774):439–444. doi:10.1038/s41586-019-1526-3.
   PubMed Web of Science ®Google Scholar
• Kaszak I, Witkowska-Piłaszewicz O, Niewiadomska Z, Dworecka-Kaszak B, Ngosa Toka F, Jurka P. Role of cadherins in cancer-A review. Int J Mol Sci. 2020;21(20):E7624. doi:10.3390/ijms21207624.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay C, Schecterson L, Gumbiner BM. E-cadherin activating antibodies limit barrier dysfunction and inflammation in mouse inflammatory bowel disease. Tissue Barriers. 2021;9(4):1940741. doi:10.1080/21688370.2021.1940741.
   PubMed Web of Science ®Google Scholar
• van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65(23):3756–3788. doi:10.1007/s00018-008-8281-1.
   PubMed Web of Science ®Google Scholar
• Loh C-Y, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):E1118. doi:10.3390/cells8101118.
   PubMed Web of Science ®Google Scholar
• Rea K, Roggiani F, De Cecco L, Raspagliesi F, Carcangiu ML, Nair-Menon J, Bagnoli M, Bortolomai I, Mezzanzanica D, Canevari S, et al. Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth. J Exp Clin Cancer Res. 2018;37(1):146. doi:10.1186/s13046-018-0796-1.
   PubMedGoogle Scholar
• Advedissian T, Proux-Gillardeaux V, Nkosi R, Peyret G, Nguyen T, Poirier F, Viguier M, Deshayes F. E-cadherin dynamics is regulated by galectin-7 at epithelial cell surface. Sci Rep. 2017;7(1):17086. doi:10.1038/s41598-017-17332-y.
   PubMedGoogle Scholar
• Pece S, Gutkind JS. Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation. J Biol Chem. 2000;275(52):41227–41233. doi:10.1074/jbc.M006578200.
   PubMed Web of Science ®Google Scholar
• Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 2004;23(8):1739–1748. doi:10.1038/sj.emboj.7600136.
   PubMed Web of Science ®Google Scholar
• D’souza B, Taylor-Papadimitriou J. Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proc Natl Acad Sci U S A. 1994;91(15):7202–7206. doi:10.1073/pnas.91.15.7202.
   PubMed Web of Science ®Google Scholar
• Hoschuetzky H, Aberle H, Kemler R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol. 1994;127(5):1375–1380. doi:10.1083/jcb.127.5.1375.
   PubMed Web of Science ®Google Scholar
• Proux-Gillardeaux V, Advedissian T, Perin C, Gelly J-C, Viguier M, Deshayes F. Identification of a new regulation pathway of EGFR and E-cadherin dynamics. Sci Rep. 2021;11(1):22705. doi:10.1038/s41598-021-02042-3.
   PubMed Web of Science ®Google Scholar
• Ling Y-H, Li T, Perez-Soler R, Haigentz M. Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. Cancer Chemother Pharmacol. 2009;64(3):539–548. doi:10.1007/s00280-008-0902-8.
   PubMed Web of Science ®Google Scholar
• Curto M, McClatchey AI. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer. 2008;98(2):256–262. doi:10.1038/sj.bjc.6604002.
   PubMed Web of Science ®Google Scholar
• Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 2003;17(9):1090–1100. doi:10.1101/gad.1054603.
   PubMed Web of Science ®Google Scholar
• Lazar CS, Cresson CM, Lauffenburger DA, Gill GN. The Na + /H + exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. Mol Biol Cell. 2004;15(12):5470–5480. doi:10.1091/mbc.e04-03-0239.
   PubMed Web of Science ®Google Scholar
• Curto M, Cole BK, Lallemand D, Liu C-H, McClatchey AI. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol. 2007;177(5):893–903. doi:10.1083/jcb.200703010.
   PubMed Web of Science ®Google Scholar
• Manwar Hussain MR, Iqbal Z, Qazi WM, Hoessli DC. Charge and polarity preferences for N-glycosylation: a genome-wide in silico study and its implications regarding constitutive proliferation and adhesion of carcinoma cells. Front Oncol. 2018;8:29. doi:10.3389/fonc.2018.00029.
   PubMed Web of Science ®Google Scholar
• Solis GP, Schrock Y, Hülsbusch N, Wiechers M, Plattner H, Stuermer CAO, Nusrat A. Reggies/flotillins regulate E-cadherin-mediated cell contact formation by affecting EGFR trafficking. Mol Biol Cell. 2012;23(10):1812–1825. doi:10.1091/mbc.e11-12-1006.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu S, Xia Y, Sun J, Denning PW. Salmonella infection upregulates the leaky protein claudin-2 in intestinal epithelial cells. PLoS One. 2013;8(3):e58606. doi:10.1371/journal.pone.0058606.
   PubMed Web of Science ®Google Scholar
• de Souza WF, Fortunato-Miranda N, Robbs BK, de Araujo WM, de-Freitas-Junior JC, Bastos LG, Viola JPB, Morgado-Díaz JA, Lee JW. Claudin-3 overexpression increases the malignant potential of colorectal cancer cells: roles of ERK1/2 and PI3K-Akt as modulators of EGFR signaling. PLoS One. 2013;8(9):e74994. doi:10.1371/journal.pone.0074994.
   PubMed Web of Science ®Google Scholar
• Peter Y, Comellas A, Levantini E, Ingenito EP, Shapiro SD. Epidermal growth factor receptor and claudin-2 participate in A549 permeability and remodeling: implications for non-small cell lung cancer tumor colonization. Mol Carcinog. 2009;48(6):488–497. doi:10.1002/mc.20485.
   PubMed Web of Science ®Google Scholar
• Singh AB, Harris RC. Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells. J Biol Chem. 2004;279(5):3543–3552. doi:10.1074/jbc.M308682200.
   PubMed Web of Science ®Google Scholar
• Takasawa K, Takasawa A, Osanai M, Aoyama T, Ono Y, Kono T, Hirohashi Y, Murata M, Sawada N. Claudin-18 coupled with EGFR/ERK signaling contributes to the malignant potentials of bile duct cancer. Cancer Lett. 2017;403:66–73. doi:10.1016/j.canlet.2017.05.033.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang Y, Zhang B, Zhang H, Zhou M, Wei M, Dong Q, Xu Y, Wang Z, Gao L, et al. Claudin-3 expression increases the malignant potential of lung adenocarcinoma cells: role of epidermal growth factor receptor activation. Oncotarget. 2017;8(14):23033–23047. doi:10.18632/oncotarget.14974.
   PubMedGoogle Scholar
• Balsamo J, Arregui C, Leung T, Lilien J. The nonreceptor protein tyrosine phosphatase PTP1B binds to the cytoplasmic domain of N-cadherin and regulates the cadherin-actin linkage. J Cell Biol. 1998;143(2):523–532. doi:10.1083/jcb.143.2.523.
   PubMed Web of Science ®Google Scholar
• Xu G, Arregui C, Lilien J, Balsamo J. PTP1B modulates the association of beta-catenin with N-cadherin through binding to an adjacent and partially overlapping target site. J Biol Chem. 2002;277(51):49989–49997. doi:10.1074/jbc.M206454200.
   PubMed Web of Science ®Google Scholar
• Sheth P, Seth A, Atkinson KJ, Gheyi T, Kale G, Giorgianni F, Desiderio DM, Li C, Naren A, Rao R. Acetaldehyde dissociates the PTP1B-E-cadherin-beta-catenin complex in Caco-2 cell monolayers by a phosphorylation-dependent mechanism. Biochem J. 2007;402(2):291–300. doi:10.1042/BJ20060665.
   PubMedGoogle Scholar
• Balsamo J, Leung T, Ernst H, Zanin MK, Hoffman S, Lilien J. Regulated binding of PTP1B-like phosphatase to N-cadherin: control of cadherin-mediated adhesion by dephosphorylation of beta-catenin. J Cell Biol. 1996;134(3):801–813. doi:10.1083/jcb.134.3.801.
   PubMed Web of Science ®Google Scholar
• Kinch MS, Petch L, Zhong C, Burridge K. E-cadherin engagement stimulates tyrosine phosphorylation. Cell Adhes Commun. 1997;4(6):425–437. doi:10.3109/15419069709004459.
   PubMed Web of Science ®Google Scholar
• Fedor-Chaiken M, Hein PW, Stewart JC, Brackenbury R, Kinch MS. E-cadherin binding modulates EGF receptor activation. Cell Commun Adhes. 2003;10(2):105–118. doi:10.1080/cac.10.2.105.118.
   PubMed Web of Science ®Google Scholar
• Perrais M, Chen X, Perez-Moreno M, Gumbiner BM, Schwarzbauer J. E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol Biol Cell. 2007;18(6):2013–2025. doi:10.1091/mbc.e06-04-0348.
   PubMed Web of Science ®Google Scholar
• Wang D, Su L, Huang D, Zhang H, Shin DM, Chen ZG. Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Mol Cancer. 2011;10(1):116. doi:10.1186/1476-4598-10-116.
   PubMedGoogle Scholar
• Li D, Lo W, Rudloff U. Merging perspectives: genotype-directed molecular therapy for hereditary diffuse gastric cancer (HDGC) and E-cadherin-EGFR crosstalk. Clin Transl Med. 2018;7(1):7. doi:10.1186/s40169-018-0184-7.
   PubMedGoogle Scholar
• Kim S, Schein AJ, Nadel JA. E-cadherin promotes EGFR-mediated cell differentiation and MUC5AC mucin expression in cultured human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2005;289(6):L1049–1060. doi:10.1152/ajplung.00388.2004.
   PubMed Web of Science ®Google Scholar
• Sehgal P, Kong X, Wu J, Sunyer R, Trepat X, Leckband D. Epidermal growth factor receptor and integrins control force-dependent vinculin recruitment to E-cadherin junctions. J Cell Sci. 2018;131:jcs206656. doi:10.1242/jcs.206656.
   PubMed Web of Science ®Google Scholar
• Inge LJ, Barwe SP, D’Ambrosio J, Gopal J, Lu K, Ryazantsev S, Rajasekaran SA, Rajasekaran AK. Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptor. Exp Cell Res. 2011;317(6):838–848. doi:10.1016/j.yexcr.2010.12.025.
   PubMed Web of Science ®Google Scholar
• Georgopoulos NT, Kirkwood LA, Walker DC, Southgate J, Anderson K. Differential regulation of growth-promoting signalling pathways by E-cadherin. PLoS One. 2010;5(10):e13621. doi:10.1371/journal.pone.0013621.
   PubMed Web of Science ®Google Scholar
• Rübsam M, Mertz AF, Kubo A, Marg S, Jüngst C, Goranci-Buzhala G, Schauss AC, Horsley V, Dufresne ER, Moser M, et al. E-cadherin integrates mechanotransduction and EGFR signaling to control junctional tissue polarization and tight junction positioning. Nat Commun. 2017;8(1):1250. doi:10.1038/s41467-017-01170-7.
   PubMedGoogle Scholar
• Hendriks WJAJ, Pulido R. Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities. Biochim Biophys Acta. 2013;1832(10):1673–1696. doi:10.1016/j.bbadis.2013.05.022.
   PubMed Web of Science ®Google Scholar
• Villamar-Cruz O, Loza-Mejía MA, Arias-Romero LE, Camacho-Arroyo I. Recent advances in PTP1B signaling in metabolism and cancer. Biosci Rep. 2021;41(11):BSR20211994. doi:10.1042/BSR20211994.
   PubMed Web of Science ®Google Scholar
• Gunawardana J, Chan FC, Telenius A, Woolcock B, Kridel R, Tan KL, Ben-Neriah S, Mottok A, Lim RS, Boyle M, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet. 2014;46(4):329–335. doi:10.1038/ng.2900.
   PubMed Web of Science ®Google Scholar
• Liu R, Sun Y, Berthelet J, Bui L-C, Xu X, Viguier M, Dupret J-M, Deshayes F, Rodrigues Lima F. Biochemical, enzymatic, and computational characterization of recurrent somatic mutations of the human protein tyrosine phosphatase PTP1B in primary mediastinal B cell lymphoma. IJMS. 2022;23(13):7060. doi:10.3390/ijms23137060.
   Google Scholar
• Mei W, Wang K, Huang J, Zheng X, Maki CG. Cell transformation by PTP1B truncated mutants found in human colon and thyroid tumors. PLoS One. 2016;11(11):e0166538. doi:10.1371/journal.pone.0166538.
   PubMed Web of Science ®Google Scholar
• Le Sommer S, Morrice N, Pesaresi M, Thompson D, Vickers MA, Murray GI, Mody N, Neel BG, Bence KK, Wilson HM, et al. Deficiency in protein tyrosine phosphatase PTP1B shortens lifespan and leads to development of acute leukemia. Cancer Res. 2018;78(1):75–87. doi:10.1158/0008-5472.CAN-17-0946.
   PubMed Web of Science ®Google Scholar
• Stuible M, Doody KM, Tremblay ML. PTP1B and TC-PTP: regulators of transformation and tumorigenesis. Cancer Metastasis Rev. 2008;27(2):215–230. doi:10.1007/s10555-008-9115-1.
   PubMed Web of Science ®Google Scholar
• Zahn M, Marienfeld R, Melzner I, Heinrich J, Renner B, Wegener S, Mießner A, Barth TFE, Dorsch K, Brüderlein S, et al. A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells. Blood. 2017;129(11):1480–1490. doi:10.1182/blood-2016-06-720516.
   PubMed Web of Science ®Google Scholar
• Zahn M, Kaluszniak B, Möller P, Marienfeld R. The PTP1B mutant PTP1B∆2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma. Carcinogenesis. 2021;42(4):517–527. doi:10.1093/carcin/bgaa144.
   PubMed Web of Science ®Google Scholar
• Wu C, Zhang L, Bourne PA, Reeder JE, Di Sant’agnese PA, Yao JL, Na Y, Huang J. Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer. Prostate. 2006;66(11):1125–1135. doi:10.1002/pros.20412.
   PubMed Web of Science ®Google Scholar
• Liu F, Sells MA, Chernoff J. Transformation suppression by protein tyrosine phosphatase 1B requires a functional SH3 ligand. Mol Cell Biol. 1998;18(1):250–259. doi:10.1128/MCB.18.1.250.
   PubMed Web of Science ®Google Scholar
• Sharma B, Xie L, Yang F, Wang W, Zhou Q, Xiang M, Zhou S, Lv W, Jia Y, Pokhrel L, et al. Recent advance on PTP1B inhibitors and their biomedical applications. Eur J Med Chem. 2020;199:112376. doi:10.1016/j.ejmech.2020.112376.
   PubMed Web of Science ®Google Scholar
• Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009;4(2):107–119. doi:10.1007/s11523-009-0114-0.
   PubMed Web of Science ®Google Scholar
• Balavenkatraman KK, Aceto N, Britschgi A, Mueller U, Bence KK, Neel BG, Bentires-Alj M. Epithelial protein-tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance. Mol Cancer Res. 2011;9(10):1377–1384. doi:10.1158/1541-7786.MCR-11-0198.
   PubMed Web of Science ®Google Scholar